Commentary · 21 Feb 2026
Conference abstractPublished 13 Jun 2016
Serum biomarkers and ovarian cancer risk: Utility for early detection and prevention
Phenomenome Discoveries Inc., Canada
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The management of ovarian cancer (OC) is difficult due to its rapid progression and the difficulty of detecting it early. Being able to detect OC early or being able to accurately identify high risk subjects for increased monitoring or for preventative surgery is critical to being able to reduce OC mortality rates. Using a non-targeted comprehensive metabolomics discovery platform, several candidate biomarkers were identified. Based upon these results, the major contributor to OC risk was hypothesized to be an overactive fatty acid desaturation and elongation system (a key process involved in cell proliferation). Low anti-inflammatory fatty acid, GTA-446 levels were also observed to contribute to OC risk. We have subsequently developed a simple metabotype test that can be performed on a single drop of blood and have successfully completed two large independent validations âÂ?Â? one from Japan (99 controls and 112 OC patients) and one from North America (1041 controls and 325 OC patients). The relative risk of OC in persons having the metabotype versus not having the metabotype was 80 in both studies with over 90% of OC subjects exhibiting the abberent metabotype. These biomarkers are based upon our unique prodrome detection technology, which identifies persons with specific metabolic abnormalities that precede the formation of specific cancers. This technology differs from traditional pathology-based cancer detection technologies in that persons who do not have these metabolic abnormalities are protected from getting the specific cancer identified by the test whereas persons exhibiting the metabolic abnormality have an elevated risk of the cancer.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Dayan Goodenowe”
